Silo Pharma (SILO) Stock Overview
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SILO Community Fair Values
Create NarrativeSee what 101 others think this stock is worth. Follow their fair value or set your own to get alerts.
Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s [test]
Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.Read more
Silo Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$3.37 |
| 52 Week Low | US$0.36 |
| Beta | 0.64 |
| 1 Month Change | -21.63% |
| 3 Month Change | -51.37% |
| 1 Year Change | -61.23% |
| 3 Year Change | -89.15% |
| 5 Year Change | -98.28% |
| Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s
May 27
Narrative update from CMCVentures
SP-26 Achieves Major Preclinical Milestone, Paving the Way for First At-Home Ketamine Therapy for Fibromyalgia.Silo Pharma has just reported encouraging preclinical results for SP-26, its innovative kNarrative update from CMCVentures
SP-26 Achieves Major Preclinical Milestone, Paving the Way for First At-Home Ketamine Therapy for FibromyalgiaSilo Pharma has just reported encouraging preclinical results for SP-26, its innovative keGroundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s
Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple scSilo Pharma spikes on pre-clinical data for Alzheimer's candidate
Oct 20Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia
Oct 03Shareholder Returns
| SILO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | 1.1% | 1.3% |
| 1Y | -61.2% | 26.4% | 15.8% |
Return vs Industry: SILO underperformed the US Biotechs industry which returned 26.3% over the past year.
Return vs Market: SILO underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| SILO volatility | |
|---|---|
| SILO Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SILO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SILO's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3 | Eric Weisblum | silopharma.com |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations.
Silo Pharma, Inc. Fundamentals Summary
| SILO fundamental statistics | |
|---|---|
| Market cap | US$4.85m |
| Earnings (TTM) | -US$5.08m |
| Revenue (TTM) | US$72.10k |
Is SILO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SILO income statement (TTM) | |
|---|---|
| Revenue | US$72.10k |
| Cost of Revenue | US$25.07k |
| Gross Profit | US$47.04k |
| Other Expenses | US$5.12m |
| Earnings | -US$5.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 65.24% |
| Net Profit Margin | -7,041.12% |
| Debt/Equity Ratio | 0% |
How did SILO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 04:06 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silo Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| I-Eh Jen | Laidlaw & Company (UK) Ltd |